Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,148,911
  • Shares Outstanding, K 73,601
  • Annual Sales, $ 40,890 K
  • Annual Income, $ -199,590 K
  • 60-Month Beta 0.99
  • Price/Sales 28.15
  • Price/Cash Flow N/A
  • Price/Book 13.74
Trade KPTI with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.57
  • Number of Estimates 7
  • High Estimate -0.21
  • Low Estimate -0.69
  • Prior Year -0.76
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.81 +9.70%
on 11/02/20
17.07 -11.25%
on 10/27/20
-0.61 (-3.87%)
since 10/23/20
3-Month
13.80 +9.78%
on 08/27/20
17.20 -11.92%
on 10/13/20
+0.95 (+6.69%)
since 08/21/20
52-Week
13.39 +13.14%
on 02/27/20
29.61 -48.83%
on 03/02/20
-1.12 (-6.88%)
since 11/22/19

Most Recent Stories

More News
Karyopharm Thera Has Returned 19.3% Since SmarTrend Recommendation (KPTI)

SmarTrend identified a Downtrend for Karyopharm Thera (NASDAQ:KPTI) on May 6th, 2020 at $19.44. In approximately 7 months, Karyopharm Thera has returned 19.34% as of today's recent price of $15.68.

KPTI : 15.15 (-2.95%)
Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology Society 2020 Annual Meeting

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported it will present positive results from the Phase...

KPTI : 15.15 (-2.95%)
Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 3 BOSTON Study Results in The Lancet

, /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the results of the Phase 3 BOSTON (rtezomib,...

KPTI : 15.15 (-2.95%)
Karyopharm to Participate at Jefferies 2020 Virtual London Healthcare Conference

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that , MD, PhD, Chief Executive Officer of Karyopharm,...

KPTI : 15.15 (-2.95%)
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one abstracts have been selected...

KPTI : 15.15 (-2.95%)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm's...

KPTI : 15.15 (-2.95%)
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 0.00% and -0.08%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?...

KPTI : 15.15 (-2.95%)
Karyopharm Therapeutics: 3Q Earnings Snapshot

NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Monday reported a loss of $53.5 million in its third quarter.

KPTI : 15.15 (-2.95%)
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended . In...

KPTI : 15.15 (-2.95%)
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma

, /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced positive top-line results from the Phase 3...

KPTI : 15.15 (-2.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

2nd Resistance Point 16.26
1st Resistance Point 15.70
Last Price 15.15
1st Support Level 14.84
2nd Support Level 14.54

See More

52-Week High 29.61
Fibonacci 61.8% 23.41
Fibonacci 50% 21.50
Fibonacci 38.2% 19.59
Last Price 15.15
52-Week Low 13.39

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar